KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$248.2 million.

  • Xenon Pharmaceuticals' Income from Continuing Operations fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • Xenon Pharmaceuticals' Income from Continuing Operations amounted to -$248.2 million in FY2024, which was down 36.07% from -$182.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$28.8 million for FY2020, and its period low was -$248.2 million during FY2024.
  • Its 3-year average for Income from Continuing Operations is -$185.3 million, with a median of -$182.4 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 30.67% in 2020, then slumped by 173.54% in 2021.
  • Xenon Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$28.8 million in 2020, then plummeted by 173.54% to -$78.9 million in 2021, then plummeted by 58.99% to -$125.4 million in 2022, then crashed by 45.43% to -$182.4 million in 2023, then tumbled by 36.07% to -$248.2 million in 2024.